Contents

Search

mecasermin (Increlex, Insmed, recombinant IGF1)

Tradenames: Increlex, FDA approved 2005 Indications: - long-term treatment of growth failure in children with severe primary IGF1 deficiency Contraindications: - not a substitute for growth hormone treatment in patients with growth hormone deficiency Dosage: - 40 to 80 ug/kg SQ BID Injection: 10 mg/mL, multiple dose glass vials (40 mg/vial) Mechanism of action: - contains human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology Manufacturers: iPlex, Insmed

General

endocrine agent insulin-like growth factor-1; mechano growth factor; MGF; somatomedin-C (IGF1, IBP1)

References

  1. Prescriber's Letter 13(2): 2006 Detail-Document#: 220215 (subscription needed) http://www.prescribersletter.com
  2. RxList http://www.rxlist.com/increlex-drug.htm